Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
- Obtaining exclusive patent rights in the US and China enhances the Company's competitive position in the global biopharmaceutical market.
- Approval for a Phase I clinical trial and successful recruitment of the first blood donor indicate progress in the development of CAR-γδ T cell technology.
- None.
The Company now has exclusive rights to a US and Chinese patent.
"With our first-in-human trial for CAR-γδ T cells set to begin in
The patent titled "Gamma Delta T Cells and a Method of Augmenting the Tumoricidal Activity of the Same" covers technologies for the clinical-scale expansion of γδ T cells from a small amount of donor peripheral blood cells, as well as the modification of the expanded γδ T cells to incorporate a CAR that enables the modified cells to recognize a wide range of cancers, including both solid and hematologic cancers.
Patent No. ZL201880023646.8, published as CN 110494558 B, is owned by A*STAR and exclusively licensed to the Company. The Company holds an exclusive, worldwide license, for use in immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
The Company received approval in January 2023 from the Health Sciences Authority (HSA) in
CytoMed's CAR-γδ T cell technology has been developed as an investigational cancer therapy to target NKG2D ligands, a type of stress-induced cancer antigens. The risk of "on-target-off-cancer" side effects may be reduced by targeting stress-induced antigens that are mainly expressed on cancer cells such as NKG2D ligands.
The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive a novel synthetic γδ NKT cells for the treatment of various types of cancers. A patent for this proprietary technology has already been granted in
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR),
About the Agency for Science, Technology, and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is
Forward Look Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical trials and the Company's R&D programs; the Company's expectations regarding the impact of the ongoing COVID-19 pandemic on its business, the Company's industry and the economy; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.
Investor and Media Contacts
Investors:
Matt Hughes
Allele Capital Partners
Media:
Toni McLaughlin
Allele Communications
tmclaughlin@allelecommunications.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/chinese-patent-granted-for-astar-spinoff-cytomed-therapeutics-licensed-allogeneic-car-gamma-delta-t-cell-technology-301889837.html
SOURCE CytoMed Therapeutics
FAQ
What technology has CytoMed obtained exclusive patent rights for?
Where will the Phase I clinical trial be conducted?